AP-2σ1 Inhibitors
The chemical class of AP-2σ1 inhibitors comprises a repertoire of compounds intricately designed to modulate cellular pathways associated with the regulation and function of AP-2σ1, a subunit of the AP-2 complex essential for clathrin-mediated endocytosis. Wortmannin, a potent phosphoinositide 3-kinase (PI3K) inhibitor, disrupts the PI3K/AKT pathway, providing indirect regulation of AP-2σ1 by orchestrating alterations in downstream signaling events. This interference in the PI3K/AKT pathway offers insights into the dynamic regulation of AP-2σ1, particularly in the context of cellular events governed by phosphoinositide signaling. U0126 and PD 98059, classified as mitogen-activated protein kinase (MEK) inhibitors, introduce perturbations to the mitogen-activated protein kinase (MAPK) pathway. This indirect modulation influences AP-2σ1 by altering downstream targets within the MAPK cascade, shedding light on the interconnected signaling networks that govern AP-2σ1 functionality. SB203580, SP600125, and Rapamycin focus on the MAPK, c-Jun N-terminal kinase (JNK), and mammalian target of rapamycin (mTOR) pathways, respectively. Through indirect regulation of AP-2σ1, these compounds intricately impact cellular processes connected to these signaling cascades, offering a nuanced understanding of the intricate regulatory mechanisms at play.
Dasatinib, a dual Src/Abl kinase inhibitor, intervenes in tyrosine kinase activity, potentially influencing AP-2σ1 through alterations in tyrosine phosphorylation events. BAY 11-7082, an NF-κB inhibitor, adds another layer of complexity by modulating NF-κB activity, thereby indirectly influencing AP-2σ1 expression. Furthermore, Cisplatin, MG-132, and GW9662, by disrupting DNA synthesis, protein degradation, and peroxisome proliferator-activated receptor gamma (PPARγ) activity, respectively, provide indirect modulation of AP-2σ1 through alterations in DNA integrity, protein turnover, and gene expression. This diverse array of compounds collectively unravels a complex interplay of mechanisms for potential AP-2σ1 inhibition. The intricate regulation of AP-2σ1 through these compounds sheds light on the multifaceted nature of cellular pathways and their impact on clathrin-mediated endocytosis, offering a rich landscape for further exploration into the intricate web of AP-2σ1 regulation within cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K/AKT pathway. By inhibiting PI3K, it influences downstream signaling events. This interference in the PI3K/AKT pathway may indirectly regulate AP-2σ1, as the protein is connected to cellular processes influenced by PI3K signaling, providing a potential indirect inhibitory effect. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAP kinase inhibitor, disrupts the MAPK signaling cascade. By inhibiting p38, it affects downstream targets. This interference in the MAPK pathway may indirectly regulate AP-2σ1, as the protein is implicated in certain cellular responses influenced by MAPK signaling, providing a potential indirect inhibitory effect. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, disrupts the PI3K/AKT pathway. By inhibiting PI3K, it influences downstream signaling events. This interference in the PI3K/AKT pathway may indirectly regulate AP-2σ1, as the protein is connected to cellular processes influenced by PI3K signaling, providing a potential indirect inhibitory effect. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059, a MEK inhibitor, disrupts the MAPK pathway. By inhibiting MEK, it influences downstream targets and modulates cellular responses. This indirect modulation of AP-2σ1 may occur through altered MAPK signaling, impacting AP-2σ1 regulation or function within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts the JNK signaling pathway. By inhibiting JNK, it influences downstream targets. This interference in the JNK pathway may indirectly regulate AP-2σ1, as the protein is involved in cellular processes impacted by JNK signaling, providing a potential indirect inhibitory effect. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway. Through mTOR inhibition, it influences downstream cellular processes. This interference in the mTOR pathway may indirectly regulate AP-2σ1, as the protein is implicated in cellular responses affected by mTOR signaling, providing a potential indirect inhibitory effect. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src/Abl inhibitor, perturbs tyrosine kinase activity. By inhibiting Src and Abl kinases, it disrupts signaling cascades, potentially influencing cellular processes linked to AP-2σ1. The indirect modulation of AP-2σ1 might occur through alterations in tyrosine phosphorylation events or cross-talk with pathways where Src and Abl kinases are implicated. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, interferes with the NF-κB signaling pathway. By modulating NF-κB activity, it indirectly influences AP-2σ1, as the protein's expression can be regulated by NF-κB. The inhibition of NF-κB may lead to altered expression levels of AP-2σ1, impacting its cellular functions indirectly. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, a DNA crosslinking agent, interferes with DNA synthesis. By forming DNA adducts, it modulates DNA structure. This indirect modulation of AP-2σ1 may occur through altered DNA integrity, impacting AP-2σ1 expression or function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, disrupts protein degradation. By inhibiting the proteasome, it modulates protein turnover. This indirect modulation of AP-2σ1 may occur through altered protein degradation processes, impacting AP-2σ1 expression or function. | ||||||